Identification of type-specific anticancer histone deacetylase inhibitors: Road to success

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 4, 2010, Pages 625-633

  Noureen, Nighat ^a   Rashid, Hamid ^a   Kalsoom, Saima ^b  

^a CAPITAL UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Pakistan)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Computational approaches; Histone deacetylase inhibitors; Histone deacetylases; In silico drug design; Isoforms; Rational drug design; Type specific

Indexed keywords

4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; BELINOSTAT; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CYCLOPEPTIDE; DEPSIPEPTIDE; DEPUDECIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PANOBINOSTAT; SHORT CHAIN FATTY ACID; SIRTUIN; TRAPOXIN A; TRAPOXIN B; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; BUTYRIC ACID DERIVATIVE; ENTINOSTAT; HYDROXAMIC ACID DERIVATIVE; TACEDINALINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPUTER MODEL; DRUG DESIGN; DRUG IDENTIFICATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; TUMOR; ANIMAL; CHEMISTRY; CLASSIFICATION; COMPUTER SIMULATION; CONFORMATION; ENZYMOLOGY; METABOLISM; NEOPLASM; REVIEW; STRUCTURE ACTIVITY RELATION; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TARGETING; MOLECULAR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR CONFORMATION; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955914870     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1324-y     Document Type: Short Survey

References (93)

1. Li Q, Xu W (2005) Novel anticancer targets and drug discovery in post genomic age. Curr Med Chem Anticancer Agents 5:53-63
2. Seddon BM, Workman P (2003) The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol 76: S128-S138
3. Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedo H, Schwartsmann G, Tattersall M, Yan S (1999) Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 10:385-390
4. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P (1999) Anticancer agents targeting signalling molecules and cancer cell environment: challenges for drug development. J Natl Cancer Inst 91:1281-1287
5. Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15:237-243
6. Chen JS, Faller DV, Spanjaard RA (2003) Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics. Curr Cancer Drug Targets 3:219-236
7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202
8. Kelly WK, Connor OAO, Marks PA (2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11:1695-1713
9. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477-483
10. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 7:759-760
11. Phiel CJ, Zhang F, Huang EY, Guenther MJ, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 76:36734-36741
12. Meinke PT, Liberator P (2001) Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr Med Chem 8:211-235
13. Juvale DC, Kulkarni VV, Deokar HS, Wagh NK, Padhye SB, Kulkarni VM (2006) 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. Org Biomol Chem 4:2858-2868
14. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
15. Karagiannis TC, El-Osta A (2007) Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds. Leukemia 21:61-65
16. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567-8572
17. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389:251-260
18. Lenfant F, Mann RK, Thomsen B, Ling X, Grunstein M (1996) All four core histone N-termini contain sequences required for the repression of basal transcription in yeast. EMBO J 15:3974-3985
19. Kouraklis G, Misiakos EP, Theocharis S (2006) Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment. Target Oncol 1:34-41
20. Chen Y, Jiang YJ, Zhou JW, Yu QS, You QD (2008) Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model 26:1160-1168
21. Cress WD, Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184:1e16
22. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41e45
23. Tanner KG, Trievel RC, Kuo MH, Howard RM, Berger SL, Allis CD, Marmorstein R, Denu JM (1999) Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. J Biol Chem 274:18157-18160
24. Gregory PD, Wagner K, Horz W (2001) Histone acetylation and chromatin remodeling. Exp Cell Res 265:195-202
25. Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70:81-120
26. Pazin MJ, Kadonaga JT (1997) What's up and down with histone deacetylation and transcription. Cell 89 (3):325-328
27. Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349-352
28. Struhl K (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12:599-606
29. Mahlknecht U, Hoelzer D (2000) Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 6:623-644
30. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D (2001) Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11:162-166
31. Lin HY, Chen CH, Lin SP, Weng JR, Chen CH (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26 (4):397-413
32. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417-435
33. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W (2001) Negative control of p53 by Sir2 alpha promotes cell survival under stress. Cell 107 (2):137-148
34. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim DK, Lee JS, Kim NK, Kim TY et al (2004) Class I histone deacetylase selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 10:5271-5281
35. Zhu P, Huber E, Kiefer F, Gottlicher M (2004) Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell Cycle 3:1240-1242
36. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479-488
37. Inche A, La Thangue NB (2006) Chromatin control and cancer drug discovery: realising the promise. Drug Discov Today 11:97-109
38. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases structure. Structure 12:1325-1334
39. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkuhler C, Marco SD (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101:15064-15069
40. Chen Y, Li H, Tang W, Zhu C, Jiang Y, Zou J, Yu Q, You Q (2009) 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem 44 (7):2868-2876
41. Zhang Y, Gilquin B, Khochbin S, Matthias P (2006) Two catalytic domains are required for protein deacetylation. J Biol Chem 281:2401-2404
42. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
43. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672-2681
44. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, Bae MK, Kim KW (2007) Regulation of the HIF-1a stability by histone deacetylases. Oncol Rep 17:647-651
45. Harms KL, Chen X (2007) Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67:3145-3152
46. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, Ferrari VA, Abrams CS, Gruber PJ, Epstein JA (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3h activity. Nat Med 13:324-331
47. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126:321-334
48. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5 (10):981-989 (Pubitemid 350080267)
49. Riester D, Hildmann C, Grune wald S, Beckers T, Schwienhorst A (2007) Factors affecting the substrate specificity of histone deacetylases. Biochem Biophys Res Commun 357:439-445
50. Marmorstein R (2001) Structure of histone acetyltransferases. J Mol Biol 311:433-444
51. Elaut G, Rogiers V, Vanhaecke T (2007) The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 13:2584-2620
52. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Coalizzi F, Altomonte M, Calabro L, Maio M (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 212:330-344
53. Garber K (2004) Purchase of Aton spotlights HDAC inhibitors. Nat Biotechnol 22:364-365
54. Fang JY (2005) Histone deacetylase inhibitors, anti-cancerous mechanism and therapy for gastrointestinal cancers. J Gastroenterol Hepatol 20:988-994
55. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163
56. Miller TA, Witter DJ, Belvedere S (2003) Histone deacetylase inhibitors. J Med Chem 46:5097-5116
57. Bi G, Jiang G (2006) The molecular mechanism of HDAC Inhibitors in anticancer effects. Cell Mol Immunol 3 (4):285-290
58. Jung M, Brosch G, Kölle D, Scherf H, Gerhäuser C, Loid P (1999) Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem 42:4669-4679
59. Grozinger CM, Schreiber SL (2002) Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9:3-16
60. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179
61. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K (1976) A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo) 29:1-6
62. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14:1497-1511
63. Wegener D, Hildmann C, Schwienhorst A (2003) Recent progress in the development of assays suited for histone deacetylase inhibitor screening. Mol Genet Metab 80:138-147
64. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2007) Determination of the class and isoform selectivity of small molecule HDAC inhibitors. Biochem J 409:581-589. doi: 10.1042/BJ20070779
65. Maia A, Altucci L (2009) Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 41:199-213
66. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193
67. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007
68. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. J Med Chem 48:3344-3353
69. Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51:1505-1529
70. Kelly WK, Marks PA (2005) Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2:150-157
71. Qian X, Ara G, Mills E, La Rochelle WJ, Lichenstein HS, Jeffers M (2008) Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 122:1400-1410
72. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42:3001-3003
73. Wang DF, Helquist P, Wiech NL, Wiest O (2005) Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 48:6936-6947
74. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592-4597
75. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, Los Frailes MD, Perez P, Krawiec J, Winkler J, Jaye M (2003) Identification of novel isoformselective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720-728
76. Pan L, Lu J, Huang B (2007) HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 4 (5):337-343
77. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299
78. Finzer P, Stohr M, Seibert N, Rosl F (2003) Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number. J Cancer Res Clin Oncol 129:107-113
79. Acharya MR, Sparreboom A, Venitz J, Figg WD (2005) Rational development of histone deacetylase inhibitors as anti-cancer agents: a review. Mol Pharmacol 68:917-932
80. Batova A, Shao LE, Diccianni MB, Yu AL, Tanaka T, Rephaeli A, Nudelman A, Yu J (2002) The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100:3319-3324
81. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963-970
82. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB (2001) Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 7:2330-2339
83. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429-22435
84. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126-133
85. Andrianov V, Gailite V, Lola D, Loza E, Semenikhina V, Kalvinsh I, Finn P, Petersen KD, Ritchie JWA, Khan N, Tumber A, Collins LS, Vadlamudi SM, Börkling F, Sehested M (2009) Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR. Euro J Med Chem 44:1067-1085
86. Kapetanovic IM (2008) Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 171 (2):165-176
87. Garrett MD, Workman P (1999) Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 35:2010-2030
88. Workman P (2001) New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr Cancer Drug Targets 1:33-47
89. Anderson AC (2003) The process of structure-based drug design. Chem Biol 10:787-797
90. Lengauer T, Zimmer R (2000) Protein structure prediction methods for drug design. Brief Bioinform 1 (3):275-288
91. Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, Pisano C, Vesci L, Barbarino M, Zuco V, Cesare MD, Zunino F (2009) Design, synthesis, and evaluation of biphenyl-4-ylacrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. doi:10.1016/j.ejmech. 2008. 11.005
92. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J (1994) Some milestones in the development of cancer chemotherapy. In: The anticancer drugs, 2nd edn. Oxford University Press, Oxford, pp 17-25
93. Liu R, Hsieh CY, Lam KS (2004) New approaches in identifying drugs to inactivate oncogene products. Semin Cancer Biol 14:13-21